Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

about

Progression inference for somatic mutations in cancer.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

P2860

Q38793244-69DB91A9-821F-4E34-B99F-52FB0E39CF0C Q52777531-5D806F0A-678A-4F67-B7AC-8F1776A72294

P2860

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

Item

http://www.wikidata.org/entity/Q42391595

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@en

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@nl

type

Item

label

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@en

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@nl

prefLabel

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@en

Immunohistochemical pattern of ...... ondary acute myeloid leukemia.

@nl

P1476

Immunohistochemical pattern of ...... condary acute myeloid leukemia

@en

P2093

David Sallman

http://www.w3.org/2001/XMLSchema#string

Eric Padron

http://www.w3.org/2001/XMLSchema#string

Jeffrey E Lancet

http://www.w3.org/2001/XMLSchema#string

Johnny Nguyen

http://www.w3.org/2001/XMLSchema#string

Kathy L McGraw

http://www.w3.org/2001/XMLSchema#string

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

Lynn C Moscinski

http://www.w3.org/2001/XMLSchema#string

Najla H Al Ali

http://www.w3.org/2001/XMLSchema#string

Rami S Komrokji

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical effect of point mutations in myelodysplastic syndromes

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.

Ubiquitination and degradation of mutant p53.

TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

P304

e320-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.143214

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Alan F List

P577

2016-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27081179

http://www.w3.org/2001/XMLSchema#string

P932

4967580

http://www.w3.org/2001/XMLSchema#string

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

about

P2860

P2860

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932